HK1098769A1 - Neutralizable epitope of hgf and neutralizing antibody binding to the same - Google Patents

Neutralizable epitope of hgf and neutralizing antibody binding to the same

Info

Publication number
HK1098769A1
HK1098769A1 HK07106374.6A HK07106374A HK1098769A1 HK 1098769 A1 HK1098769 A1 HK 1098769A1 HK 07106374 A HK07106374 A HK 07106374A HK 1098769 A1 HK1098769 A1 HK 1098769A1
Authority
HK
Hong Kong
Prior art keywords
hgf
neutralizing antibody
same
antibody binding
neutralizable epitope
Prior art date
Application number
HK07106374.6A
Other languages
English (en)
Inventor
Junho Chung
Youngmi Hur
Original Assignee
Nat Cancer Ct
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nat Cancer Ct filed Critical Nat Cancer Ct
Publication of HK1098769A1 publication Critical patent/HK1098769A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Toxicology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK07106374.6A 2003-11-11 2007-06-13 Neutralizable epitope of hgf and neutralizing antibody binding to the same HK1098769A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020030079482A KR100556660B1 (ko) 2003-11-11 2003-11-11 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
PCT/KR2004/002888 WO2005044848A1 (fr) 2003-11-11 2004-11-09 Epitope de hgf pouvant etre neutralise et anticorps neutralisant lie a celui-ci

Publications (1)

Publication Number Publication Date
HK1098769A1 true HK1098769A1 (en) 2007-07-27

Family

ID=36660022

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07106374.6A HK1098769A1 (en) 2003-11-11 2007-06-13 Neutralizable epitope of hgf and neutralizing antibody binding to the same

Country Status (11)

Country Link
US (2) US7408043B2 (fr)
EP (1) EP1694700B1 (fr)
JP (1) JP4446393B2 (fr)
KR (1) KR100556660B1 (fr)
CN (2) CN101434654A (fr)
AT (1) ATE476992T1 (fr)
AU (1) AU2004287743B2 (fr)
DE (1) DE602004028651D1 (fr)
ES (1) ES2346887T3 (fr)
HK (1) HK1098769A1 (fr)
WO (1) WO2005044848A1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7220410B2 (en) 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
JP5014143B2 (ja) 2005-10-14 2012-08-29 学校法人福岡大学 膵島移植における移植膵島障害抑制剤
BRPI0617664B8 (pt) 2005-10-21 2021-05-25 Chugai Pharmaceutical Co Ltd uso de um anticorpo que reconhece a il-6 para a produção de uma composição farmacêutica para tratar o enfarte do miocárdio ou suprimir a remodelagem ventricular esquerda depois do enfarte do miocárdio
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
WO2007061029A1 (fr) * 2005-11-25 2007-05-31 Keio University Agent thérapeutique pour le cancer de la prostate
PT2289909E (pt) 2005-11-30 2015-02-10 Abbvie Inc Método de rastreio, processo de purificação de globulómeros a-beta não difundíveis, anticorpos selectivos contra os referidos globulómeros a-beta não difundíveis e processo para o fabrico dos referidos anticorpos
KR20140087058A (ko) 2005-11-30 2014-07-08 애브비 인코포레이티드 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도
ES2685915T3 (es) 2006-01-27 2018-10-15 Keio University Agentes terapéuticos para enfermedades que implican neovascularización coroidea
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
EP2025346B1 (fr) 2006-04-07 2016-08-10 Osaka University Promoteur de régénération musculaire
BRPI0712222B1 (pt) * 2006-06-02 2021-10-13 Aveo Pharmaceuticals, Inc. Proteína de ligação isolada que se liga ao fator de crescimento de hepatócito humano (hgf), seu uso e método de produção, ácido nucléico, vetor de expressão, célula hospedeira, e métodos para produzir um polipeptídeo que compreende uma região variável da cadeia pesada de imunoglobulina e para produzir um polipeptídeo que compreende uma região variável da cadeia leve de imunoglobulina
KR101196184B1 (ko) 2006-06-02 2012-11-01 아베오 파마슈티컬즈, 인크. 간세포 성장 인자 (ｈｇｆ) 결합 단백질
KR100829972B1 (ko) 2006-07-14 2008-05-16 재단법인서울대학교산학협력재단 항-ｈｇｆ/ｓｆ 인간화 항체 및 이의 제조방법
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008090901A1 (fr) 2007-01-23 2008-07-31 Shinshu University Inhibiteur de rejet chronique
US20100311767A1 (en) * 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
CA2692165A1 (fr) * 2007-06-25 2008-12-31 Amgen Inc. Compositions d'agents de liaison specifiques vis-a-vis du facteur de croissance des hepatocytes
EP2305306B1 (fr) 2008-06-05 2016-02-10 National Cancer Center Inhibiteur de neuro-invasion
PA8849001A1 (es) * 2008-11-21 2010-06-28 Lilly Co Eli Anticuerpos de c-met
EP2545077B1 (fr) 2010-03-10 2018-10-31 Genmab A/S Anticorps monoclonaux contre c-met
ES2684475T3 (es) 2010-04-15 2018-10-03 Abbvie Inc. Proteínas que se unen a beta amiloide
JP6051049B2 (ja) 2010-05-28 2016-12-21 中外製薬株式会社 抗腫瘍ｔ細胞応答増強剤
EP2402370A1 (fr) * 2010-06-29 2012-01-04 Pierre Fabre Médicament Nouvel anticorps pour le diagnostic et/ou le pronostic du cancer
MX358739B (es) 2010-08-14 2018-09-03 Abbvie Inc Star Proteinas de union a amiloide beta.
AU2011325097B2 (en) * 2010-11-03 2015-05-21 Argenx Bvba Anti c-Met antibodies
KR20120130658A (ko) * 2011-05-23 2012-12-03 주식회사 파멥신 펩타이드가 융합된 이중표적항체 및 그 용도
US9631011B2 (en) 2012-03-15 2017-04-25 Snu R&Db Foundation Gremlin-1 antibody
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
WO2014108854A1 (fr) 2013-01-09 2014-07-17 Fusimab Ltd. Anticorps anti-hgf et anti-ang2 monospécifiques, et anticorps anti-hgf/anti-ang2 bispécifiques
US9732150B2 (en) * 2013-03-14 2017-08-15 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
US9481725B2 (en) 2013-03-14 2016-11-01 Alderbio Holdings, Llc Antibodies to HGF and compositions containing
US9062104B2 (en) 2013-03-14 2015-06-23 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
US10501737B2 (en) 2013-09-30 2019-12-10 Chugai Seiyaku Kabushiki Kaisha Method for producing antigen-binding molecule using modified helper phage
JP2017516458A (ja) 2014-03-24 2017-06-22 ジェネンテック， インコーポレイテッド ｃ−ｍｅｔ拮抗剤による癌治療及びｃ−ｍｅｔ拮抗剤のＨＧＦ発現との相関
WO2016060297A1 (fr) * 2014-10-16 2016-04-21 주식회사 파멥신 Anticorps à double cible doté dune aptitude à la liaison à vegfr-2 et à c-met
WO2018203545A1 (fr) 2017-05-02 2018-11-08 国立研究開発法人国立精神・神経医療研究センター Procédé de prédiction et d'évaluation d'un effet thérapeutique dans des maladies associées à il-6 et à des neutrophiles
US11692037B2 (en) 2017-10-20 2023-07-04 Hyogo College Of Medicine Anti-IL-6 receptor antibody-containing medicinal composition for preventing post-surgical adhesion
CA3231704A1 (fr) * 2021-09-13 2023-03-16 The Board Of Regents Of The University Of Texas System Proteines de liaison a l'antigene trem2 et leurs utilisations
WO2023056527A1 (fr) * 2021-10-07 2023-04-13 The University Of Queensland Molécules protéiques et leurs utilisations
KR20230148433A (ko) 2022-04-14 2023-10-25 주식회사 셀랩메드 키메릭 항원 수용체 및 hgf 중화항체의 조합 요법
KR20230148435A (ko) * 2022-04-14 2023-10-25 주식회사 셀랩메드 키메릭 항원 수용체 및 hgf 결합 억제 물질의 조합 요법

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1241574A (zh) * 1998-07-02 2000-01-19 中国人民解放军第四军医大学 抗肝癌单克隆抗体HAb25及其单链抗体和双功能抗体

Also Published As

Publication number Publication date
US7408043B2 (en) 2008-08-05
JP2007532097A (ja) 2007-11-15
EP1694700A4 (fr) 2007-10-31
CN101434654A (zh) 2009-05-20
JP4446393B2 (ja) 2010-04-07
EP1694700B1 (fr) 2010-08-11
AU2004287743B2 (en) 2008-10-09
ES2346887T3 (es) 2010-10-21
ATE476992T1 (de) 2010-08-15
CN1878790A (zh) 2006-12-13
DE602004028651D1 (de) 2010-09-23
EP1694700A1 (fr) 2006-08-30
CN100447158C (zh) 2008-12-31
KR100556660B1 (ko) 2006-03-10
AU2004287743A1 (en) 2005-05-19
KR20050045419A (ko) 2005-05-17
US20090023894A1 (en) 2009-01-22
WO2005044848A1 (fr) 2005-05-19
US20070036789A1 (en) 2007-02-15

Similar Documents

Publication Publication Date Title
HK1098769A1 (en) Neutralizable epitope of hgf and neutralizing antibody binding to the same
IL258880A (en) Compounds of diarylhydantoin
IL244803A0 (en) Human anti-beta7 antibodies and their use
IL245462A0 (en) Antagonists of human origin against cmet
UA93201C2 (ru) АНТИТЕЛО, KOTOPOE НЕЙТРАЛИЗУЕТ ЧЕЛОВЕЧЕСКИЙ TGF-b1
YU28503A (sh) Humanizovana anti-lt-beta-r antitela
MXPA06014510A (es) Composiciones y metodos para tratar trastornos inflamatorios.
MY140767A (en) Compounds, methods and compositions
MX2007002525A (es) Compuestos de difeniletileno y usos de los mismos.
WO2009142738A3 (fr) Compositions et procédés utilisables en matière de diagnostic et de traitement du cancer
WO2003075855A3 (fr) Anticorps diriges contre l'antigene cancereux tmeff2 et utilisations de ceux-ci
WO2004031105A3 (fr) Utilisation d'antigenes a33 et de jam-it
AU2003215381A1 (en) EGFRvIII SPECIFIC MONOCLONAL ANTIBODY AND EGFRvIII RIBOZYMES AND USE TO DETECT, TREAT OR PREVENT EGFRvIII ASSOCIATED CANCER
WO2007007152A3 (fr) Anticorps anti-madcam utilises pour le traitement de cancers metastatiques et du chlorome
MX2007002451A (es) Uso de inhibidores de la conversion de hormona tiroidea.
DK1368023T3 (da) Anvendelse af buprenoprphin til behandling af urininkontinens
UA2986U (uk) Спосіб лікування розсіяного склерозу